Furthermore, inhibition of Akt1/2 and PI3K with Akt inhibitor VIII and LY294002, respectively, sensitizes hepatocellular carcinoma-derived cells for apoptotic cell death, which indicates that Akt1/2 and PI3K are prone targets for anticancer therapies [81]. Here, AKT1 is linked to hepatocellular carcinoma.